1.2011年10月22日-25日，美國眼科學(xué)年會在美國佛羅里達(dá)州的奧多蘭舉行，圖為奧多治會議中心。

　�。�1.The Orange County Convention Center in Orlando, Florida, played host to the American Academy of Ophthalmology （AAO） 2011 Annual Meeting, held October 22 to 25, 2011.）

${FDPageBreak}

　　2.今年會議的亮點是：

　　（1）飛秒激光輔助白內(nèi)障手術(shù)被視為“重大進(jìn)展”

　�。�2）MRSA眼部感染呈上升趨勢，但治療滯后

　�。�3）青光眼患者用藥依從性差異很大

　�。�4）眼保健醫(yī)生比家庭醫(yī)生有更多筋骨勞傷的苦惱

　�。�5）白內(nèi)障手術(shù)有助于阿爾茨海默氏癥患者

　�。�6）iPad有助于提高視力不佳患者的閱讀能力

　�。�2.Among this year's highlights:

　�。�1）Femtosecond laser-assisted cataract surgery is seen as a “major advance”

　�。�2）MRSA eye infections are on the rise, but treatment is lagging

　�。�3）Medication compliance in patients with glaucoma varies widely

　�。�4）Eye-care physicians have more musculoskeletal woes than family physicians

　�。�5）Cataract surgery helps patients with Alzheimer's disease

　　（6）The iPad improves the reading ability of patients with low vision）

${FDPageBreak}

　　3.飛秒激光助白內(nèi)障手術(shù)一臂之力

　�。�3.Femtosecond Laser-Assisted Cataract Surgery a Major Advance

　　A study provides strong evidence of the increased safety and effectiveness of laser-mediated emulsification of cataracts compared with phacoemulsification. The approach uses femtosecond laser technology, which delivers near-infrared light to create precise subsurface cuts at depths that are greater than those possible using conventional approaches. Stephen Slade, MD, from Slade & Baker Vision Center in Houston, Texas, who was not involved in the study, described this technique as “the single most significant advancement in cataract surgery in the last 40 years.”）

${FDPageBreak}

　　4.Novel眼插入改善糖尿病性黃斑水腫

　�。�4.Novel Eye Insert Improves Diabetic Macular Edema

　　An intravitreal insert that releases a sustained and controlled amount of the corticosteroid fluocinolone acetonide improved visual acuity for as long as 3 years in a study of patients with diabetic macular edema. This result “is particularly exciting, as it demonstrates that a single insert can provide rapid and sustained improvement in visual acuity for up to 36 months,” said David Brown, MD, from Retinal Consultants of Houston, Methodist Hospital, Texas, during his presentation.）

${FDPageBreak}

　　5.視網(wǎng)膜中央靜脈阻塞1年新藥物可維持視力

　�。�5.New Drug Maintains Visual Acuity in Central Retinal Vein Occlusion at 1 Year

　　Patients with macular edema caused by central retinal vein occlusion who received injections of VEGF Trap-Eye （Regeneron Pharmaceuticals） on an as-needed basis after receiving the drug once a month for 6 months maintained their initially improved visual acuity, according to 1-year results of the COPERNICUS trial. “This is good information. VEGF Trap-Eye works and appears to have some durability of effect when given on an as-needed basis,” said study presenter Julia Haller, MD, ophthalmologist-in-chief at the Wills Eye Institute and professor and chair of the Department of Ophthalmology at Thomas Jefferson University in Philadelphia, Pennsylvania.）

（責(zé)任編輯：李波祺 ）